## MEDICATION MONITORING REPORT

All patients taking preventive therapy, adults and children, should be assessed, face to face, on a monthly basis for adverse

Client's Name: Date of Birth: / /

																			11011	ւթւ ա	3303	31110	114
44,5	100 1	04011	0110	0000		5	.,,	11 1 5	5	11,5 0	0110	1010	4 1110	/110111	.y •.	uiu		J.					
preve	entive	e the	rapy	or a	res	pons	sible	adu	lt ca	ring	for a	a chi	ld o	n pr	even	tive	ther	apy :	shou	ıld b	e qu	esti	01
ing s	ympt	toms	or s	signs	con	siste	ent w	ith	liver	dam	nage	or o	ther	adv	erse	effe	ects.				-		
<del></del>		1		1		1		ı		i				ı		ı		i					
Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	N	Y	
-																							t
<u> </u>																				<u> </u>			1
																							Ī
-																							ł
<u> </u>																				<u> </u>			1
																							İ
-																							ł
<u> </u>																				<u> </u>			1
																							İ
-																						<del>                                     </del>	ł
<u> </u>																				<u> </u>			1
																							t
-																							ł
<u> </u>																						<u> </u>	1
	ons sphe clift adverse preventions	ons specifing the clinical adverse repreventivelying symptom	ons specific to he clinical face adverse reaction preventive the wing symptoms	ons specific to TB he clinical face to f adverse reactions preventive therapy ying symptoms or s	ons specific to TB sym he clinical face to face adverse reactions occu preventive therapy or a ving symptoms or signs	ons specific to TB symptome clinical face to face asse adverse reactions occurring preventive therapy or a response symptoms or signs con	ons specific to TB symptoms at the clinical face to face assessment adverse reactions occurring be preventive therapy or a responsiving symptoms or signs consistent.	ons specific to TB symptoms and dr he clinical face to face assessment of adverse reactions occurring between preventive therapy or a responsible wing symptoms or signs consistent w	ons specific to TB symptoms and drug she clinical face to face assessment of sy adverse reactions occurring between repreventive therapy or a responsible adulying symptoms or signs consistent with	ons specific to TB symptoms and drug side the clinical face to face assessment of symptomators adverse reactions occurring between regular preventive therapy or a responsible adult caving symptoms or signs consistent with liver	ons specific to TB symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective the clinical face to face assessment of symptoms and drug symptoms of specific assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms and drug side effective clinical face to face assessment of symptoms are all face to face as a face	ons specific to TB symptoms and drug side effects. The clinical face to face assessment of symptoms and adverse reactions occurring between regularly scheol preventive therapy or a responsible adult caring for a round symptoms or signs consistent with liver damage	ons specific to TB symptoms and drug side effects. Roughe clinical face to face assessment of symptoms and drug adverse reactions occurring between regularly scheduled preventive therapy or a responsible adult caring for a chird ching symptoms or signs consistent with liver damage or of	ons specific to TB symptoms and drug side effects. Routine he clinical face to face assessment of symptoms and drug side adverse reactions occurring between regularly scheduled more preventive therapy or a responsible adult caring for a child owing symptoms or signs consistent with liver damage or other	ons specific to TB symptoms and drug side effects. Routine labor he clinical face to face assessment of symptoms and drug side effects adverse reactions occurring between regularly scheduled monthly preventive therapy or a responsible adult caring for a child on proving symptoms or signs consistent with liver damage or other adverse.	ons specific to TB symptoms and drug side effects. Routine laborato he clinical face to face assessment of symptoms and drug side effects. adverse reactions occurring between regularly scheduled monthly every preventive therapy or a responsible adult caring for a child on preventing symptoms or signs consistent with liver damage or other adverse	ons specific to TB symptoms and drug side effects. Routine laboratory in the clinical face to face assessment of symptoms and drug side effects, not adverse reactions occurring between regularly scheduled monthly evaluate preventive therapy or a responsible adult caring for a child on preventive ring symptoms or signs consistent with liver damage or other adverse effects.	ons specific to TB symptoms and drug side effects. Routine laboratory monit he clinical face to face assessment of symptoms and drug side effects, nor for adverse reactions occurring between regularly scheduled monthly evaluation preventive therapy or a responsible adult caring for a child on preventive therapy or signs consistent with liver damage or other adverse effects.	ons specific to TB symptoms and drug side effects. Routine laboratory monitoring the clinical face to face assessment of symptoms and drug side effects, nor for the productions occurring between regularly scheduled monthly evaluations.  The preventive therapy or a responsible adult caring for a child on preventive therapy symptoms or signs consistent with liver damage or other adverse effects.	ons specific to TB symptoms and drug side effects. Routine laboratory monitoring for the clinical face to face assessment of symptoms and drug side effects, nor for the prome adverse reactions occurring between regularly scheduled monthly evaluations.  preventive therapy or a responsible adult caring for a child on preventive therapy showing symptoms or signs consistent with liver damage or other adverse effects.	ons specific to TB symptoms and drug side effects. Routine laboratory monitoring for tox he clinical face to face assessment of symptoms and drug side effects, nor for the prompt a cadverse reactions occurring between regularly scheduled monthly evaluations.  preventive therapy or a responsible adult caring for a child on preventive therapy should bying symptoms or signs consistent with liver damage or other adverse effects.	ons specific to TB symptoms and drug side effects. Routine laboratory monitoring for toxicity he clinical face to face assessment of symptoms and drug side effects, nor for the prompt assess adverse reactions occurring between regularly scheduled monthly evaluations.  preventive therapy or a responsible adult caring for a child on preventive therapy should be quiving symptoms or signs consistent with liver damage or other adverse effects.	preventive therapy or a responsible adult caring for a child on preventive therapy should be question symptoms or signs consistent with liver damage or other adverse effects.

If any of these or other signs or symptoms occur during preventive therapy, patients should repeatedly be advised to report immediately to the clinic or health care provider.

Of individuals receiving isoniazid, 10% to 20% will develop some mild abnormality of liver function tests, e.g., an elevated aspartate aminotransferase (AST; SGOT). These abnormalities tend to resolve even if isoniazid is continued.

Persons with history of hepatic disease or other persons at risk of hepatitis:

These individuals, especially alcohol abusers, injection drug users and persons taking any other concurrent medications, should have baseline liver function tests, with subsequent biochemical monitoring, according to the patient's risk of hepatitis and at the physician's discretion.

If any of these results exceed 3 to 5 times the upper limit of normal, discontinuation of isoniazid should be strongly considered.